Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Underweight and raises the price target from $14 to $15.
Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Underweight and raises the price target from $14 to $15.